Factors that influence adherence to antiretroviral therapy among adults at Nekemte Referral Hospital in Ethiopia by Amsalu Belew Zeleke
FACTORS THAT INFLUENCE ADHERENCE TO 
ANTIRETROVIRAL THERAPY AMONG ADULTS AT NEKEMTE 
REFERRAL HOSPITAL IN ETHIOPIA 
 
 
 
 
 
by 
 
 
 
 
 
Amsalu Belew Zeleke 
 
 
 
 
 
submitted in accordance with the requirements 
 
 
 
 
 
for the degree of 
 
 
 
 
 
MASTER OF PUBLIC HEALTH 
 
 
 
 
at the 
 
 
 
 
UNIVERSITY OF SOUTH AFRICA 
 
 
 
SUPERVISOR: PROF GB THUPAYAGALE-TSHWENEAGAE 
 
 
July 2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Student number: 43252931 
 
DECLARATION 
 
 
I declare that FACTORS THAT INFLUENCE ADHERENCE TO ANTIRETROVIRAL 
THERAPY AMONG ADULTS AT NEKEMTE REFERRAL HOSPITAL IN ETHIOPIA is 
my own work and that all the sources that I have used or quoted have been indicated 
and acknowledged by means of complete references and that this work has not been 
submitted before for any other degree at any other institution. 
 
 
 
 
 
 
 
Dr Amsalu Belew Zeleke      25 July 2012 
Full names        Date 
 
  
FACTORS THAT INFLUENCE ADHERENCE TO 
ANTIRETROVIRAL THERAPY AMONG ADULTS AT NEKEMTE 
REFERRAL HOSPITAL IN ETHIOPIA 
 
STUDENT NUMBER: 43252931 
STUDENT:   Amsalu Belew Zeleke 
DEGREE:    Master of Public Health 
DEPARTMENT:  Health Studies, University Of South Africa 
SUPERVISOR:  Prof GB Thupayagale-Tshweneagae 
 
Abstract 
 
The objectives of the study were (1) to quantify adherence rate among the study 
participants in the ART unit and (2) to identify factors that contribute to non-adherence. 
This cross sectional study was carried out at Nekemete referral clinic. Data was 
collected using a self-developed structured questionnaire where a total of 338 
participants grouped into adherent and non-adherent based on a score derived from an 
adherence assessment were interviewed. Data was analysed using the Statistical 
Package for Social Sciences (SPSS) version 17.0. By using multivariate analysis of 
variables identified as correlates of adherence, non-adherence was common among 
those; with age between 18-30 yrs, with no education, who were not married, who had 
no pipe water supply, those with no electricity in the house, who perceived had no 
access to assistance from providers, who perceived the health care providers (HCPs) 
did not keep information confidentially, who had a language barrier with providers, and 
who were treated with a psychiatric illness. The study concludes that adherence is 
multi-factorial and varies significantly by individual and care setting. Psychosocial 
factors were found to impact adherence and should be analysed in more detail by 
further studies. Three psychosocial factors were independently associated with poor 
adherence: the study found that patients perceiving poor access; those perceiving 
problems in information confidentiality (and possibly experiencing stigmatisation); and 
having psychiatric morbidity (and possibly with less social support) are more likely to be 
non-adherent. Furthermore, individuals without electricity and those without piped water 
supply, implying low income, are at risk for non-adherence. 
 
KEY CONCEPTS: Adherence to antiretroviral therapy; antiretroviral drugs; CD4+ cell 
count; clinical response; cross-sectional study; drug resistance; antiretroviral therapy;  
immunologic response; multivariate analysis; virological response; viral suppression. 
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
 
1.1 INTRODUCTION 
 
Patient adherence is a dynamic phenomenon broadly affected by patient, medications, 
disease, provider and systems factors. Poor adherence has been associated with a 
number of factors in the United States of America (USA) and western Europe, including 
treatment side-effects; complex regimens; lack of social support; mental illness; active 
substance use; stigma; low level of literacy; poverty issues (transportation problems, 
food insecurity), asymptomatic status of patient prior to initiation of treatment, poor 
understanding of regimen, inadequate pharmacy service and lack of confidence or trust 
in the health care service (Horizons … 2004:18-19; Tusiime, Orelland & Bangsberg 
2008:209; Rachlis, Mills & Cole 2011:8; Ingersoll & Cohen 2008:2; Federal HAPCO and 
Federal MOH 2007:75). 
 
1.2 BACKGROUND INFORMATION 
 
Ethiopia initiated a fee-based antiretroviral therapy (ART) programme in July 2003, and 
in January 2005, a free ART programme was launched and implemented across the 
country. ART services rapidly expanded over a few years. Facilities providing ART 
service have grown from three in 2004 to 481 in June 2009 (in 136 hospitals and 345 
health centres) (HIV/AIDS Prevention and Control Office [HAPCO] 2008-2009:37). 
According to United Nations Programme of HIV/AIDS (UNAIDS) (2010:98), the adult 
treatment coverage need in Ethiopia, according to 2010 guideline, ranges from 52% to 
65%. These figures illustrate the magnitude of the task to provide prevention, care and 
treatment and support services for all who need them and strongly indicate the need to 
come up with strategies to maximise long-term ART adherence to ensure success as 
Ethiopia scale up ART programmes countrywide. 
 
It is clear that adherence to ART is a multidimensional phenomenon comprising multiple 
interrelated factors, and as such, requires a multidisciplinary approach  
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(El-Sadr, Affrunti, Gamble & Zerbe 2010:5-6; Horizons … 2004:51). The lack of 
adherence to treatment is an interaction between the patient, the regimen, the providers 
of therapy, and the environment in which this occurs (Tusiime et al 2008:208). This 
interaction is the context in which adherence does or does not occur. The issue of 
adherence requires expertise, collaboration, and coordination of services within primary 
care, specialist care, social service settings and the broad multidisciplinary team 
(UNAIDS 2010:106). 
 
Non-adherence to treatment regimens is not unique to people living with HIV (PLWH). 
From the literature, it is clear that non-adherence is ubiquitous. For example, adherence 
to anti-hypertension medication regimen varies between 26% and 51%. Data on 
patients with depression reveal that between 40% and 70% adhere to antidepressant 
therapies. In PLWH, reports of adherence range from 37% to 83% (World Health 
Organization [WHO] 2003:8). 
 
In a cohort study adherence to protease inhibitor therapy of 95% or greater was 
required to optimise virological outcome for the human immunodeficiency virus (HIV) 
positive persons. Eighty per cent to 94,9% adherence has been associated with failure 
to achieve complete viral suppression in 61% of patients (Paterson, Swindells, Mohr, 
Brester, Vergis, Squier, Wagener & Singh 2000:22). Many of the barriers associated 
with non-adherence in resource-rich settings also apply to resource-limited settings. 
These include frequency of dosing, younger age, being single, depression, male 
gender, forgetfulness, being too busy or away from home, regimen complexity, 
psychosocial factors, intolerance, alcohol consumption and a lack of belief in efficacy of 
ART.  
 
Nonetheless, there are many additional barriers that are unique to resource-limited 
settings such as the cost of medication, long distance to the treatment centres, 
stigma/fear of disclosure, medication stock outs, a lack of access and privacy, and 
language barrier between the patient and the provider (Tusiime et al 2008:209).  
 
However, contrary to early concerns, adherence in developing countries has been found 
to be generally better than adherence in developing countries. Most studies done in 
resource-limited settings have found excellent rates of adherence with subsidised/free 
ART (adherence levels of greater than 90%) with the majority of them from SSA. While 
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this is largely unknown, it is clear that severe poverty does not preclude excellent 
adherence and there are several potential explanations for this. People in these settings 
start therapy at later stages of disease and may have more dramatic improvements in 
health and functional status with initiation of therapy and these likely reinforce early 
adherence. HIV positive parents who have lost spouses and other relatives because of 
acquired immunodeficiency syndrome (AIDS) may be caring for large numbers of 
dependent children, which has been described as a central motivation for adherence 
(Tusiime et al 2008:210).  
 
1.3 RESEARCH PROBLEM 
 
Adherence is not well addressed as a central component at health facilities and patient 
levels in Ethiopia. A significant proportion of all hospital admissions are due to drug non-
adherence. If adherence is low, treatment failure will occur and the likelihood of 
development of resistant virus is high.  
 
1.4 RESEARCH PURPOSE 
 
The purpose of this study is to investigate the factors that influence adherence in terms 
of the magnitude of non-adherence and major factors contributing to non-adherence. 
 
1.5 RESEARCH OBJECTIVES 
 
The objectives of the study are to 
 
• quantify the adherence rate among the study participants in the ART unit 
• identify factors that influence adherence 
 
1.6 FOUNDATIONS OF THE STUDY 
 
The researcher has adapted the following framework to analyse determinants of 
adherence at an individual patient level for an ambulatory client who is living in the 
community. 
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Figure 1.1     A Conceptual Map of Factors that Influence Adherence  
Source (Adapted from): Horizons…2004:18 
 
 
 
 
 
 
Figure 1.1 Conceptual map of factors that influence adherence 
(Adapted from Horizons … 2004:18) 
 
1.7 SIGNIFICANCE OF THE STUDY 
 
Evidence related to adherence to ART in Ethiopia is scarce. Literature search by the 
researcher has shown that there are only a handful of studies conducted in Ethiopia that 
are related to adherence to ART (Tiyou, Belachew, Almseged & Biadgilign 2010:1; 
Gusdal, Obua, Andualem, Wahstrom, Tomson, Peterson, Ekstrom, Thorson, Charlker & 
Forschen 2009:1382; Markos, Alemayehu & Davey 2008:176). In light of this, it is 
relevant to investigate and document the prevalence and socio-economic, behavioural 
and other factors linked to adherence to ART. The study, therefore, will provide further 
insight helpful in designing and implementing evidence-based interventions in regional 
Patient variables: socio-
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psychosocial factors, HIV 
knowledge 
 
 
Treatment regimen 
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Patient– 
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as well as national programmes by policy-makers and any governmental or non-
governmental organisations working with PLWH in creating conducive environment for 
optimising adherence to ART.  
 
1.8 ETHICAL CONSIDERATIONS 
 
The ethical protection of respondents was maintained throughout this study. Before the 
study began, ethical clearance was obtained from the Higher Degrees Committee of the 
Department of Health Studies at Unisa (Annexure A). Institutional consent was obtained 
from the medical director’s office of Nekemte Hospital after communicating through a 
formal letter (Annexure B).  
 
1.9 RESEARCH METHODOLOGY 
 
1.9.1 Research design 
 
This is a quantitative, cross-sectional, institution-based study with descriptive and 
analytic components.  
 
1.9.2 Setting 
 
The study was conducted at a district hospital, Nekemte Hospital, located in the 
Western part of Ethiopia, and the South Western part of Oromiyya region. This is a 
referral hospital in the East Wollega zone with a catchment population of 2,8 million 
people in 2011. 
 
1.9.3 Population and sample 
 
The study population in this study consisted of all PLWH on ART in Nekemte Hospital 
aged 18 years old and above who were started on ART in Nekemte Hospital and had 
been taking ART for a minimum of 12 months at the time of the interview. 
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1.10 OPERATIONAL DEFINITIONS USED IN THE RESEARCH REPORT 
 
ART adherence is the ability of the person living with HIV to be involved in choosing, 
starting, managing and maintaining a given ART regimen to control HIV replication and 
improve the immune function. It means taking the correct doses of drugs at the correct 
time and in the correct way (such as with the right type of food or fluid) and sticking to 
the treatment plan. It also means looking after drugs to make sure they are safe and 
effective to use. Adherence is different from compliance in that the latter is not based 
upon shared decision-making between the patient and provider (Horizons … 2004:16).  
 
Non-adherence to ART includes the missing a dose or doses of antiretroviral drugs; 
stopping medicine for a day or days; taking the medicine at the wrong time and taking 
the medicine without dietary instructions (Horizons … 2004:17).  
 
Level of adherence: The percentage of prescribed doses swallowed by the patient 
following instructions given by the provider.   
 
Adherence rate: The proportion/percentage of patients who adhered to the regimen 
according to the definition of adherence based on the score by the operational definition 
for adherence. 
 
Calculation of the adherence assessment score: The assessment score was 
calculated by asking the patient skipped doses, or delayed doses for more than two 
hours, over the last seven days, and calculating the adherence rate by the following 
formula: 
 
Number of doses taken/Number of doses supposed to take for seven days X 100% 
 
ART adherence level is said to be “Good” if >95%.  
 
Patients were asked for missed doses for the last 24 hours, 72 hours, and seven days. 
But for assessment, the past seven days were taken and assessment was done by 
counting how many dose(s) were missed (taking also delayed doses for ≥2 hours as 
missed) the previous seven days. 
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A patient will be labelled as adherent if he/she took all doses in the previous seven 
days, and non-adherent if he/she skipped or took with delay of ≥2 hours even a single 
dose in the previous seven days. This is based on the above formula and considering 
good (≥95%) or near to perfect adherence necessary for ART. 
 
1.11 ORGANISATION OF THE DISSERTATION 
 
The dissertation is divided in the following chapters: 
 
Chapter 1:  Introduction and background information of the research study 
 
Chapter 2: Literature review for the research study 
 
Chapter 3: Research methodology 
 
Chapter 4: Research results 
 
Chapter 5: Discussion of the study 
 
Chapter 6: Conclusions, limitations and recommendations 
 
1.12 CONCLUSION 
 
This introductory chapter provided an overview of the study. It includes an introduction 
to the chapter, background information on adherence and ART as used in Ethiopia. The 
research problem, significance of the study, purpose of the study, objectives of the 
study, methods of research used in the study and the ethical considerations as used in 
the study. The chapter concludes by providing the structure for the study. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1 INTRODUCTION 
 
Chapter 2 presents a review of the literature related or relevant to the factors that 
influence adherence to ART among adults. The chapter’s review of literature is 
structured as follows: 
 
• Overview of HIV infection and antiretroviral therapy 
• Overview of antiretroviral therapy in resource-limited settings 
• Goals of antiretroviral therapy 
• Adherence to antiretroviral therapy 
• Measurement instruments used for adherence assessment 
• Factors that influence adherence to antiretroviral therapy 
• Patient variables 
• Clinical setting 
• Treatment regimen 
• Conclusion 
 
2.2 OVERVIEW OF HIV INFECTION AND ANTIRETROVIRAL THERAPY 
 
A key factor to the successful treatment of chronic HIV is good adherence to ART. 
Studies demonstrate the importance of adherence to achieve the best virological 
response, lower the risk that drug resistance will develop, and reduce morbidity and 
mortality. These benefits critically depend on patients achieving and maintaining high 
levels of medication adherence. Very high level of adherence (>95%) is required for 
ART to be effective and to prevent the emergence of resistant viral strains (Horizons … 
2004:16; Tusiime et al 2008:207). 
 
The overview of infection and ART are discussed under goals of antiretroviral therapy 
and overview of antiretroviral therapy in resource-limited settings. 
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2.2.1 Goals of antiretroviral therapy 
 
Antiretroviral therapy constitutes the election therapy for chronic HIV infection. It was 
first introduced in the developed world in 1996. Since it delays clinical progression, it 
increases survival significantly and diminishes hospital admissions and associated 
costs. It consists of at least three drugs from the three original drug classes: 
 
(1) Nucleoside reverse transcriptase inhibitors (NRTI) and nucleotide reverse 
transcriptase inhibitors (NtRTI) 
(2) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
(3) Protease inhibitors (PI) (Merry & Flexner 2008:171; Federal HAPCO and Federal 
MOH 2007:50-62) 
 
From the point of view of patients, the goals of antiretroviral therapy can be summarised 
as follows:  
 
• durable suppression of viral replication to undetectable levels in the blood (<50 
copies/mm3 in routine viral load assay 
• stabilisation or improvement in immune function as measured by CD4 cell count 
• improvement in quality of life by reduction of HIV-related complications, and 
improvement in overall survival 
 
Individuals living with HIV who receive treatment and optimal care live longer and 
healthier lives. With ART, HIV can be approached as a chronic, manageable condition 
rather than a shorter-term issue of palliative care (Rouleau, Fortin, Trottie, Lalonde, 
Lapointe, Cote, Routy, Matte, Tsarevsky & Baril 2011:53).  From a public health point of 
view, it results in possible reduction in transmission of HIV. 
 
Specific antiviral regimens should be selected with the goal of maximising viral 
suppression, minimising side effects and preventing or delaying the emergence of viral 
resistance in order to preserve future treatment options. For the success of ART, in 
addition to appropriate adherence counselling, time of initiation of therapy, use of 
effective first-line regimen and proper monitoring for side effects are important (Rouleau 
et al 2011:52, 53). 
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2.2.2 Overview of antiretroviral therapy in resource-limited settings 
 
The agreement between the United Nations Programme on HIV/AIDS (UNAIDS) and 
major pharmaceutical companies for antiretroviral drugs price reductions, primarily for 
Sub-Saharan Africa (called the Accelerating Access Initiative) and the Durban AIDS 
conference held in 2000 brought about a breakthrough for access to ART in resource-
poor settings. Subsequently, the United Nations General Assembly Special Session 
(UNGASS) on HIV/AIDS declared that antiretroviral treatment is an essential 
component of HIV and AIDS prevention strategies. The World Health Organization 
(WHO) included antiretroviral drugs in the essential medicines list and formulated 
guidelines for the development of a public health approach to treatment of HIV 
infections in resource-limited settings (RLS). New and substantial funding agencies, 
such as the World Bank, the Global Fund to Fight AIDS, TB and Malaria (GFATM), and 
President’s Emergency Plan for AIDS Relief (PEPFAR) were established. These 
developments, together with decreasing drug prices, have resulted in successful ART 
scale-up in RLS (WHO, UNAIDS, UNICEF 2011:2; Lange, Katabira & Sow 2008:615).  
 
The scale-up in SSA has been the most successful. At the end of 2009, 37% of adults 
and children eligible for ART were receiving it in the region overall (UNAIDS 
2010:96).The rapid scale-up of ART is, however, associated with the challenges of 
ensuring that HIV care delivered to clients is of the highest quality. An unintended 
consequence of treatment scale-up is the inevitable emergence of HIV drug resistance 
(HIV DR) in populations even when patient adherence to ART is optimally supported. 
Sustaining and expanding ART coverage in RLS will depend upon the ability of ART 
programmes to deliver ART in a way that minimises the emergence of HIVDR. 
Fortunately, current evidence demonstrates that HIVDR in RLS has neither emerged 
nor been transmitted to the degree that had initially been feared; many reports indicate 
optimal treatment follow-up of ART patients in SSA (Mills, Nachega, Buchan, Orbinski, 
Attaran, Singh, Rachlis, Wu, Cooper, Thabane, Wilson, Guyatt & Bangsberg 2009:685; 
Rosen, Fox & Gill 2007:1695-1696). 
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2.3 ADHERENCE TO ANTIRETROVIRAL THERAPY 
 
Adherence to antiretroviral therapy will be discussed under adherence as a concept, 
measurement instruments used in the assessment of adherence and factors that 
influence adherence to ART. 
 
2.3.1 Adherence as a concept 
 
Adherence means a collaborative process between the patient and provider in addition 
to sticking to medications and other health services (Laufs, Rettig-Ewen & Böhm 
2010:260). The WHO adherence project defines adherence as “the extent to which a 
person’s behaviour – taking medication, following a diet, and/or executing lifestyle 
changes, corresponds with agreed recommendations from a health care provider” 
(WHO 2003:3). The patient plays a more active role in his/her treatment and makes a 
commitment to follow the prescribed regimen as best as possible.  
 
Adherence is often used synonymously with compliance but the two concepts differ. For 
clinicians, compliance usually means “the extent to which the patient takes the 
medications as prescribed”, it makes the provider task-oriented rather than patient-
oriented and the patient passive receiver of command, implying thereby a lack of 
discussion and mutual decision-making required facilitating adherence (WHO 2003:3-4). 
Instead of “compliance,” it has been suggested that the term adherence be used. It puts 
more of a burden on the clinician to form a therapeutic alliance with the patient, which 
enables the patient to discuss and to be part of decision-making. Thereby it increases 
behavioural compliance and possibly enhancing the therapeutic effect of the medication 
administered (Laufset al 2010:264). 
 
A key factor to the successful treatment of HIV is good adherence to ART, which is 
critical to obtain its full benefits: maximal and durable suppression of viral replication, 
reduced destruction of cluster differentiation T-lymphocyte (CD4) cells, prevention of 
viral resistance, promotion of immune reconstitution and slowed disease progression. 
Several studies have indicated that adherence greater than 95% is required for ART to 
achieve clinical, immunologic and virologic success (Steel, Nwokike & Joshi 2007:2). 
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Non-adherence can vary from missing one dose of a medication to missing a single 
dose of all three or four medications to missing multiple doses or all doses a day or 
week. Not observing instructions regarding dietary or fluid intake or not taking 
medications at prescribed time intervals also constitutes non-adherence. Several 
studies have shown that a significant number of patients are non-adherent to ART with 
varying levels of adherence to antiretroviral drugs ranging from 37% to 83% depending 
on the type of antiretroviral drug under study (Steel et al 2007:3) and with the average 
non-adherence to ART ranging from 55% to 77% among patients in Africa and the USA, 
respectively (Mills et al 2009:679). Non-adherence can lead to inadequate suppression 
of viral replication, continued destruction of CD4 cells, progressive decline in immune 
function and fast disease progression. Non-adherence is also an important reason for 
the emergence of multi-drug resistant viral strains (Steel et al 2007:4). 
 
2.3.2 Measurement instruments used for adherence assessment 
 
Adherence with ART can be difficult to assess. Rates of virological failure can give a 
general indication of the level of compliance within a clinic population. This information 
can be augmented by knowledge of viral resistance patterns so that virological failure 
due to resistance can be distinguished from that due to poor adherence to medication 
schedules. There is no single superior or gold standard instrument for measuring 
adherence and using multiple instruments brings more accurate result than using one 
instrument (Steel et al 2007:8). 
 
Adherence is traditionally estimated in several direct and indirect ways; self-report, pill 
count, pharmacy refill tracking, electronic devices, and measuring drug levels are some 
of them. Patient self-report is simple to collect, but it may be inaccurate if patients wish 
to deceive the provider or simply cannot recall medication schedules well enough. 
Patients often tend to overestimate compliance.  
 
At times, however, patient self-reporting can be sufficiently accurate and has been 
shown to correlate with virological response to ART. Pill counts, whether by patient or 
provider, often provide more accurate information than patient self-reporting, although 
overestimates of compliance are also possible by this measure. Drug-refill tracking is an 
important tool to trace those patients who are missing appointments, and as result, to 
 
13 
conclude poor adherence because of running out of drugs. Besides, it is a useful early 
warning indicator of virological and immunologic failure.  
 
However, there are patients who have perfect adherence to drug-refill but it cannot be 
confirmed if they are swallowing their pills or not. Although the measuring of drug levels 
can provide important information about compliance, drug level assays are expensive 
and not generally available. The correlation between blood levels and therapeutic effect 
may not be as strong as it is for intracellular levels for some agents.  
 
Finally, drug levels at best provide information only about recent compliance and may 
therefore overestimate overall compliance. Electronic monitoring systems can record 
each time the bottle is opened. Even such systems may not provide a fully accurate 
indication of compliance, because they are not able to determine the number of pills 
removed or swallowed (Steel et al 2007:6-7). 
 
2.3.3 Factors that influence adherence to antiretroviral therapy 
 
Most of our understanding to adherence to antiretroviral therapy comes from studies in 
resource rich settings (RRS). Adherence study results in RRS may not, however, be 
replicated to RLS because of differences in patient dynamics in the two settings. 
 
According to Tusiime et al (2008:208), a number of factors have been associated with 
non-adherence to ART, which can be categorised to include: patient factors, treatment 
regimen, disease characteristics, clinical settings and patient-provider relationship.  
 
2.3.3.1 Patient variables 
 
Studieson adherence show that it is impossible to predict adherence based on patient 
demographics such as age, gender, ethnicity and socioeconomic status, which patients 
will achieve high adherence (Haubrich, Little, Currier, Forthal, Kemper, Beall, Johnson, 
Dube, Hwang & McCutchan 1999:1099-1107; Fong, Ho, Fung, Lee, Tse, Yuen, Sin & 
Wong 2003:133-138). 
 
Tusiime et al (2008:208-209) said studies report conflicting evidence about the 
association between socio-demographic factors and adherence behaviour. When an 
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association is found, the direction is towards lower levels of adherence with younger 
age, being single, non-white race/ethnicity, and lower income, which may be due to 
uncontrolled confounding by other factors. 
 
On the other hand, a number of psychosocial factors have been found to strongly 
influence adherence. These include psychiatric morbidity (particularly depression), 
active drug use or alcohol use, stressful life events, lack of social support, HIV and 
AIDS related stigma and fear, harmful cultural and traditional practices and poor health 
literacy (Panelon Antiretroviral … 2012:K1; Tusiime et al 2008:208).  
 
A patient’s knowledge of his medication regimen and his/her understanding of the 
relationship between non-adherence and build-up of resistance to medication have 
been found to predict better adherence (Panelon Antiretroviral … 2012:K1). 
 
2.3.3.2 Clinical setting 
 
Although existing data is limited, aspects of the clinical setting may be associated with 
improved adherence. Ease of access to medication refills, convenience in scheduling 
appointments, and presence of social workers/peer educators has been associated with 
good adherence (Reda & Biadgilign 2012:3). According to Tusiime et al (2008:208), 
other aspects of the clinical setting that may contribute to better adherence include: 
 
• access to ongoing primary care or decentralisation of ART services 
• involvement in a dedicated adherence programme 
• availability of transportation or geographical access of health facilities 
• perceived privacy of the clinical environment 
• extended ART service over the weekends and holidays 
• satisfaction with past experiences in the health care system 
 
Although correlates of adherence are described, the factors that influence adherence 
are almost as unique as the people taking the drugs (Tusiime et al 2008:208). 
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2.3.3.3 Patient-provider relationship 
 
Provider-related determinants include a trusting patient-provider relationship and 
provider experience. The patient-provider relationship plays an important role in 
improving adherence to prescribed medications in chronic diseases. A friendly, 
supportive and non-judgmental attitude of health care providers is believed to be a 
motivating factor for adherence to ART. Perceived trust or confidentiality in providers 
has been found to influence adherence positively (Tusiime et al 2008:208). 
 
2.3.3.4 Treatment regimen 
 
The main factors related to the treatment regimen are the number of pills prescribed, 
the specific type of antiretroviral drugs, and medication adverse effects and side effects. 
ART consists of a complex regimen that can require swallowing multiple pills a day and 
it will be even worse if the patient is taking other medications for prophylaxis or 
treatment of opportunistic infections. It is sometimes further tightened with specific food 
and fluid related instructions. These are often difficult to follow for patients and 
contribute to poor adherence. The higher the pill burden, the lower is the adherence 
(Tusiime et al 2008:208). 
 
2.3.3.5 Disease characteristics  
 
Disease-related predictors include stage of HIV infection and presence of prior-
opportunistic infections (OI). Patients who have had previous OI may understand the 
severity of their illness and tend to adhere to their treatment (Tusiime et al 2008:208). 
 
2.4 CONCLUSION 
 
The use of ART has resulted in reduced AIDS incidence and mortality. However, little is 
known about the therapeutic process necessary to promote acceptance of and 
adherence to ART among HIV-positive persons in RLS. Studies have confirmed that 
adherence to ART regimens is of fundamental importance to ART success. Even minor 
deviations from prescribed drug schedules can result in early emergence of resistant 
viral strains (Gardner, Burman, Steiner, Anderson & Bangsberg 2009:9). 
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CHAPTER 3 
 
RESEARCH METHODOLOGY 
 
 
3.1 INTRODUCTION 
 
This chapter outlines and justifies the methods used in this study. Four main topics 
discussed are:  
 
• research design 
• sampling 
• methods of data collection  
• methods of data analysis 
 
As part of data analysis, issues around internal and external validity of data were 
considered. Lastly, the summary of the chapter is given. 
 
3.2 RESEARCH DESIGN 
 
A research design is a blueprint for conducting the study that maximises control over 
factors that could interfere with the validity of the findings (Burns & Grove 2005:2; 
Stommel & Wills 2004:3). Quantitative design will be adopted for this study. Stommel 
and Wills (2004:3) refers to quantitative research as “the systematic development of 
new knowledge via a process of assembling empirical evidence”, and Burns and Grove 
(2005:24) point out that quantitative studies seek to describe variables, investigate 
relationships among variables, and determine cause and effect relationships between 
variables. 
 
3.2.1 Rationale for choosing a quantitative cross-sectional design 
 
Time pressure, resources and financial constraints of conducting this study forced the 
researcher to conduct a cross-sectional study. A cross-sectional study is the simplest 
variety of descriptive or observational epidemiology that can be conducted on 
 
17 
representative samples of a population. It is used as a useful way to gather information 
(Joubert & Ehrlich 2007:7). 
 
3.3 RESEARCH METHOD 
 
3.3.1 Study setting and period 
 
Ethiopia is a low-income country in east Africa, with a total population of 73,8 million 
according to the 2007 population and housing census (CSA 2012:3). The overall adult 
HIV prevalence in Ethiopia has remained low. The HIV prevalence among adults aged 
15 to 49 in the 2011 Ethiopian Demographic and Health Survey (EDHS) is 1,5% and it 
was 1,4% in the 2005 EDHS (CSA 2012:234). The estimate in 2012 is 1,3% based on 
Ethiopian Demographic and Health Survey (EDHS) 2011 and antenatal care (ANC) 
2009 (Federal HAPCO 2012:1).  
 
This study was conducted at a district hospital, Nekemte Hospital, located in the 
Western part of Ethiopia, and the south-western part of Oromiyya region. This is a 
referral hospital in the East Wollega zone with a catchment population of 2,08 million 
people in 2011. The hospital has 12 general practitioners and nine specialists (two 
general surgeons, two gynaecologists, one internist, one paediatrician, one orthopaedic 
surgeon, and two ophthalmologists) and has 178 in-patient beds.  
 
The hospital provides general outpatient and in-patient services, including surgical and 
obstetric emergency care. Infectious diseases account for most of the inpatient and 
outpatient visits. The hospital has been providing voluntary counselling and testing 
(VCT), services for more than a decade and provider initiated testing and counselling 
(PITC) services for the past four years. A free ART service was started in January 2006. 
The adult HIV prevalence (among women and men aged 15 to 49 who were tested) of 
the Oromiyya region was 1.0% in 2011 EDHS (CSA 2012:235).The study period was six 
weeks and it started in 1 June until 12 July 2012.   
 
 
 
 
 
Figure 3.1 Map of the Oromiyya regional state of Ethiopia  
(Oromia map 2005: [1])
East Wollega Zone 
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3.3.2 Study population 
 
The study population/target population were all PLWH who are currently on ART in 
Nekemte Hospital. 
 
3.3.3 Sampling, sampling procedure, sample size and the sample population 
 
3.3.3.1 Sampling 
 
Sampling involves selecting a group of people, events, behaviours, or other elements 
from a larger population or universe, with which to conduct a study. The objective of the 
sampling theory is to determine mathematically the most effective way of acquiring a 
sample that would accurately reflect the population under study. A probability-sampling 
plan better ensures precision in the accurate estimation of the population parameters, 
thus reducing sampling errors (Burns & Grove 2005:365). For the current study, a 
sampling procedure was designed to ensure it represented of the study population. 
 
3.3.3.2 Sampling procedure 
 
The concept of systematic sampling was applied when choosing participants for 
structured interviews. Systematic sampling refers to selecting, from a population list or 
“sampling frame,” every kth individual, using a starting point selected randomly. The 
population size is divided by the desired sample size, giving k, the size of the gap 
between elements selected from the list. For this study, Nekemte Hospital was selected 
conveniently. The participants were only included if they fulfilled the criteria, i.e. patients 
who were18 years of age and older and who were12 months and more on ART. These 
participants were recruited when they came into the clinic to collect their medication or 
had doctors’ appointments by using systematic random sampling. The first participant 
was selected at random. Then each fourth individual exiting from the ART clinic was 
included as patients come to the clinic to attend according to their appointment and 
queue. 
 
The sampling frame (adult appointment calendar/logbook) contained names of patients 
on ART who were expected to attend the health facility in the time decided to collect 
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data. The sampling frame contains all patients on ART as every patient is appointed 
every month for follow-ups. 
 
3.3.3.3 Sample size 
 
Patients meeting the inclusion criteria were selected until the required sample size was 
obtained. The sampling interval was: K=Sampling frame (N)/Sample size (n) =1462/340 
=4.3≈4.The starting participant was selected randomly and every fourth person on the 
list was included in the sample. The health facility, Nekemte Hospital, where the study 
was carried out, had 1 462 registered patients who were on ART at the time of the 
study. 
 
The sample was determined using the single population proportion formula by Le 
(2003:452). The assumptions were that the sample was representative; the sampling 
error was small, the sample was viable in the context of funds available for the research 
study, systematic bias was controlled in a better way and results from the sample study 
will be generalisable. 
 
Assuming random sampling and normal distribution, a response rate of 90%, 50% for 
anticipated proportion and a significance level of 0,05, the sample size needed was 
calculated using the formula below:   
=  
Where: 
p= anticipated population proportion (50%, since there is no previous study done) 
d=the precision required on either side of the proportion (=0,05) 
z=the cut-off value of the Normal distribution (=1,96 at level of significance of 
0,05) 
=  =384,16=384 since sampling is from a finite population of 
N=1462(Adults  18 years of age currently on ART in the hospital (adult ART 
clinic). 
n= = =304 
For a response rate of 90%, = =338,6 , where = the final sample 
size. 
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3.3.3.4 Sample population 
 
The sample population was composed of PLWH aged 18 years and above who were 
started on ART in Nekemte Hospital and currently taking ART in Nekemte Hospital ART 
clinic, and have been taking ART for a minimum of one year. 
 
The inclusion criteria comprised of outpatients who were at least 18 years of age, and 
were willing to participate in the study (able to give informed consent), and not seriously 
sick, and have been taking ART for a minimum of one year.  
 
The following patients were excluded from the study: 
 
Those patients on second line regimen after treatment failure, and those on short-
course ART for post-exposure prophylaxis (PEP) and for prevention of vertical 
transmission of HIV. 
 
3.3.4 Ethical issues related to sampling 
 
The age of consent in Ethiopia is 15 years old and above; the study has complied with 
that (FMOH and Federal HAPCO 2007:4) which requires that study participants can 
consent from the age of 15. The ethical protection of the respondents was maintained 
throughout this study. The following ethical principles were adhered to: 
 
3.3.4.1 Informed consent 
 
Informed verbal consent of participants was sought and recorded in writing. The 
objectives of the study were discussed with each participant. The participants were told 
that there would be no incentive but would have benefits in the long run, that the study 
had no risks and that they had full right to discontinue the questioning at any time during 
the session. The cell phone number of the principal investigator was given to the 
participants for any queries. All this information was given both orally and in written 
leaflet to each participant.  
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3.3.4.2 Risk and discomfort 
 
Participating in this research project had no risks or discomfort. However, to avoid 
participants feeling like their time was being wasted, it was explained to them that 
answering questions would take a maximum of 30 minutes.  
 
3.3.4.3 Benefits 
 
Participants were told that their participation in the study might not give those direct 
benefits, but their participation would enable the researcher to identify barriers and 
facilitators of adherence to ART, which subsequently can be utilised by the relevant 
health care workers to provide evidence-informed and appropriate ART adherence 
counselling and support based on the study. 
 
3.3.4.4 Incentive 
 
There were no incentives for participating in the study. 
 
3.3.4.5 Confidentiality 
 
The information that we collected from this research project was kept confidential. 
Information collected from the study was stored in a file, which does not have names of 
respondents on it, but a code number assigned to it. Which number belongs to which 
name is kept in secrecy indefinitely. 
 
3.3.4.6 Right to refuse or withdraw 
 
Participants were told that they had the full right to refuse to participate in the research 
(they could choose not to respond to some or all questions). It was further explained to 
the participants that if they did not wish to participate in the study it would not affect their 
treatment or health care that they get from this health facility in any way. Participants 
were also told that they had full right to withdraw from the interview at any time they 
wished to, without losing any of their right as clients in this health institution. 
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3.3.5 Data collection 
 
3.3.5.1 Data collection approach and method 
 
Quantitative method of data collection was applied by using only one mode of data 
collection: asking questions (self-report). Face-to-face exit interview was selected as the 
preferred mode of administration of the written questionnaire as it was personal (one-
on-one) setting. ART outpatients were the sources of data.  
 
3.3.5.2 Development and testing of the data collection instrument 
 
Researchers who have tried to measure adherence have realised that there is no gold 
standard by which adherence can be quantified (Steel et al 2007:8). This study had 
selected and developed the structured questionnaire as a measurement tool. 
 
The questionnaire was adopted from the public domain, but five questions were 
formulated from the scratch in an effort to make the questionnaire comprehensive and 
complete. However, pilot testing with members of the target population was conducted 
for preliminary evaluation of individual items: comparison of response rate of newly 
formulated items with those of other items and variation in responses for all items was 
checked. It was found that all the items have very good response rate and reasonably 
high variation in responses. After the questionnaire was developed, 20 structured 
interviews were conducted. This was after translation and preparation of the 
questionnaire (Oromifa), which is a local language used in the district. The items were 
translated by the principal investigator and back translated by another skilful interpreter. 
 
3.3.5.3 Characteristics of the data collection instrument 
 
The structured questionnaire was composed of predominantly closed questions and 
some open questions, which were rated for quantification. The information that was 
collected included age, sex, marital status, religion, household size and quality of 
housing, level of education, employment and average monthly income, knowledge of 
HIV and AIDS, and knowledge, attitude, perception and practice on use of antiretroviral 
drugs by patients; patients’ perception towards health care providers and setting; 
patients’ disease history, psychosocial support, psychological health and coping 
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methods and, self-recall of missed doses: Patients were asked how they took their 
medicines in the last, three and seven days prior to interview.  
 
This has the advantage of a short time-span (seven days) and gives a chance and time 
for the interviewee to try to recall three times over the last seven days, which means 
that memory of medicine intake is likely to be good. However, patients may feel 
ashamed to report specific instances of non-adherence that occurred in the seven days 
prior to visiting the health facility, especially if they have to specify exactly when they 
failed to take a pill.  
 
3.3.5.4 Data collection process 
 
Data was collected by one medical doctor (who was the supervisor) and four nurses 
trained on basic ART who were not employees of the hospital to make the participants 
free from possible fear of judgment by the staff during subsequent visits. Training was 
given on data collection techniques, and there was observation during data collection 
process and 5% of the collected data was assessed daily for its completeness for 
implementation of early correctional measures for the following day activities.   
 
Data was collected for six weeks to get all the finite population according to the 
sampling method selected, as every ART patient is appointed every one month for refill 
and reassessment. The daily patient flow according to appointment was found to be 60 
to 70 clients. Assuming this and participating every fourth client seven days a week (as 
the ART clinic is open in the weekends) attained the calculated sample size. The two 
weeks were added to get those who have come days after the appointment date 
because of different reasons. 
 
3.3.5.5 Ethical considerations related to data collection 
 
• Permission to carry out the research study was obtained from the Higher 
Degrees Committee of the Department of Health Studies at Unisa for ethical 
clearance (Annexure A). 
• Data was collected after getting written consent from the medical director’s office 
of Nekemte Hospital after communicating through a formal letter (Annexure B).  
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3.3.6 Data analysis 
 
Data was sorted, coded, and entered into the computer using a Statistical Package for 
Social Sciences (SPSS) software version 16.0. Data was presented using charts, 
graphs and frequency tables.  
 
The primary outcome variable was adherence with ART. This was defined as patient 
self-report of whether any antiretroviral drug had been skipped the previous day, the 
previous three days and the previous seven days. For the comparison assessment, the 
adherence in the previous seven days was used. 
 
Self-reported adherence to all antiretroviral agents was summarised as the ratio of the 
average daily number of antiretroviral drugs adhered to correctly according to the 
standard instructions over the total number of antiretroviral medication prescribed. The 
results were then expressed as a percentage, and patients aggregated into two groups 
consisting of those adherent (took >95% antiretroviral drugs correctly) and non-
adherent (took <95% antiretroviral drugs correctly). 
 
The analysis consisted of basic summaries of patient characteristics, univariate binary 
logistic analysis of the relation between dose skipping and various factors, and 
multivariate logistic regression analysis to adjust values of the dependent variable for 
the influence of the likely confounding explanatory variables. 
 
By using binary logistic regression model, the magnitude of the association between the 
different variables in relation to the adherence to treatment was measured through odds 
ratios (OR) and their 95% confidence interval (CI). 
 
Comparisons for which P-values were below 0,05 were considered statistically 
significant. 
 
3.4 INTERNAL AND EXTERNAL VALIDITY OF THE STUDY 
 
By using adequate sample size and pre-tested questionnaire, which was adapted from 
standardised questionnaires for Ethiopian setting, precision of the measurement 
instruments is optimised. 
 
26 
By using strong inclusion and exclusion criteria and using random selection of study 
subjects from the study population, and making the participants/sample population 
representative of the study population, selection bias is prevented in this study. To 
minimise information bias, all variables were measured in the same way on all 
participants; and, since it is a cross-sectional study design, unlike a case-control study, 
data collectors knew little about the participants which can help to additionally prevent 
information bias in the study. Furthermore, the source of data is a primary source (at 
point of service) and external validity is maintained.   
 
3.4.1 Pretesting of the research instrument 
 
The research instrument was pre-tested to increase the validity and reliability of the 
responses. The questionnaire was pretested using the same procedure and with a 
similar target group. Pre-testing was done on 20 respondents; these respondents did 
not participate in the actual study. 
 
The pre-tested findings showed that the questionnaires were well developed. The 
research assistants were well trained before participating in the study. Regular cross 
checking, inspection and scrutinising of information on the research instruments were 
done to ensure accuracy, relevance, completeness, consistency and uniformity of the 
data collected. 
 
3.5 CONCLUSION 
 
Chapter 3 outlined the research methods used to answer the research question. The 
population sampling, data collection, instrument, ethical considerations, and data 
analysis were also discussed. Chapter 4 will present the results of the study. 
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CHAPTER 4 
 
RESEARCH RESULTS 
 
 
4.1 INTRODUCTION 
 
The research objectives for the study were to quantify adherence rate among the study 
participants in the ART unit and to identify factors that influence adherence. The 
findings of the study aimed at meeting the study objectives and are presented according 
to the sequence in the questionnaire and are presented according to the following sub-
headings:  
 
• socio-demographic data 
• health care facility and providers influence on adherence to ART 
• disease factors 
• psychosocial factors (family support and illness factors) 
• HIV and ART knowledge 
• reasons for missing antiretroviral drugs 
• patient reported rate of adherence 
• overview of research findings 
 
Tables, graphs, charts and descriptions are used to present the findings and ends up 
with a conclusion. 
 
4.2 SOCIO-DEMOGRAPHIC DATA 
 
4.2.1 Age of participants 
 
The age of study participants ranged from 18 years to 51 years and above. The 
majorities were between 20 and 50, and 52% of the participants are between 31 and 40. 
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Table 4.1 Age of participants 
 
Age in years Number Percentage 
18 to 19 8 2,4 
20 to 30 111 32,8 
31 to 40 176 52,1 
41 to 50 39 11,5 
Over 50 4 1,2 
TOTAL 338 100,0 
 
4.2.2 Gender of participants 
 
A total of 126 male and 208 female subjects participated in the study as depicted in 
figure 4.1; the rest four of the participants’ gender was not filled in. 
 
 
 
 
Figure 4.1 Gender of participants 
 
 
4.2.3 Marital status 
 
A total of 146 of the patients interviewed were married, 79 never married, 70 widows, 41 
separated and one participant was divorced. The majority being married (43,3%) 
followed by single (23,4%). Depicted in the figure below in percentages: 
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Figure 4.2 Marital status 
 
4.2.4 Level of education 
 
Their average educational attainment was relatively high, 27,6% had completed high 
school and 21,4% had a tertiary education qualification. Participants who are in primary 
and secondary schools were 85 and 93 respectively. Participants who never went to 
school were 87. Seventy-two of the participants have attended tertiary education. 
 
 
 
Figure 4.3 Educational level 
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4.2.5 Average monthly income  
 
Different levels of income were reported with 63,1% reporting to have less than 500 birr 
per month, 10% between 500 and 1000 birr, 5,6% b/n 1000 and 1500 birr and 21,3% 
more than 1 500 birr. It is resented in the following figure as percentage. 
 
 
 
 
Figure 4.4 Monthly incomes 
 
 
4.2.6 Religion 
 
Of the participants, 57,4% were Orthodox, followed by Protestant (28%), Muslim (15%), 
and Catholic (0,3%). Also depicted below: 
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Figure 4.5 Religion 
 
4.3 HEALTH CARE FACILITY AND PROVIDERS INFLUENCE ON ADHERENCE 
TO ART 
 
4.3.1 Respectful treatment   
 
Ninety seven percent of the patients perceive that the health care provider (HCP) 
involves them as a partner and supports their decisions after counselling. 
 
4.3.2 Confidentiality 
 
Ninety seven per cent of the patients feel that the information about their disease and 
treatment history is being treated with confidentiality. 
 
4.3.3 HCP access 
 
Ninety seven percent of the patients witnessed that the HCPs are easily available for 
consultation and other supply services in the facility. 
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4.3.4 Communication easiness/language barrier 
 
Only 5% reported they had a language barrier during their visit to communicate with the 
HCPs. 
 
4.3.5 Information given to patients 
 
Ninety percent of the participants reported that the HCPs helped them to understand 
their care. 
 
These characteristics are depicted below: 
 
 
 
Figure 4.6 Patient-provider relationship and clinical setting characteristics of 
respondents 
 
4.4 DISEASE FACTORS 
 
Fifty five per cent of patients said they were diagnosed with HIV about one to three 
years ago, while 38% said four to six years have passed since they were diagnosed. 
Eighty six per cent of the patients had HIV-related treatment at the time of the interview 
and 83% had been hospitalised in the past year prior to interview: 
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Figure 4.7 Time when patients were diagnosed with HIV 
 
 
 
Figure 4.8 HIV-related treatments currently 
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Figure 4.9 Hospitalisation over last one year 
 
4.5 PSYCHOSOCIAL FACTORS (FAMILY SUPPORT AND ILLNESS FACTORS) 
 
About 16% of the participants reported that they were treated for a psychiatric illness in 
the past. About 10% reported to have had depression. Only 2% reported active 
substance use while on ART. Some 75% claimed to have no one to talk to while the rest 
(25%) reported to have someone close to talk to while depressed. Around 84% had 
disclosed their statuses to their family members and 13% reported that they were 
receiving help from their family. 
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Figure 4.10 Disclosure to family 
 
 
 
Figure 4.11 History of treatment for psychiatric illness 
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Figure 4.12 Feelings of depression 
 
 
 
Figure 4.13 Active substance use while on ART 
 
4.6 HIV AND ART KNOWLEDGE 
 
Half of the respondents were found to have a very good knowledge of HIV and AIDS 
including ways of transmission while 2% had poor knowledge. 
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Although 25,3% accepted that they had no idea about the benefits of ART and 17,1% 
claimed that they had some doubts about antiretroviral drugs, 57,4% believed the ART 
would benefit them. When further assessments were done on those who claimed that 
they knew that ART would benefit them, 59% were found to have a very good 
knowledge about how ART works.  
 
The proportion of participants knowledgeable (that is all answers correct) on issues 
concerning ART medicines was found to be 247/340 (73%) while the proportion of 
participants knowledgeable about HIV and AIDS was 172/334 (52%). 
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Figure 4.15 ART knowledge 
 
 
 
 
Figure 4.16 Assessment of level of knowledge of ART among those who said 
that they knew how it works 
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4.7 REASONS FOR MISSING TO TAKE ANTIRETROVIRAL DRUGS 
 
All 338 participants were asked to choose from 13 reasons for missing antiretroviral 
drugs listed in the questionnaire. They were advised to choose as many reasons as 
they wanted. The results were as follows:  
 
• 16 respondents asserted that they simply forgot to take their medication 
• 16 reported that they missed their doses due to being too busy 
• 13 patients missed their pills when they were away from home 
• eight patients ran out pills 
• five had a change in their daily routine 
• five did not want others to notice that they were taking medicine 
 
Other barriers to treatment included: fear of side effects (two respondents), being 
burdened by too many pills to take (two respondents), feeling sick (two respondents), 
feeling asleep (one respondent), feeling depressed or overwhelmed (one respondent), 
too many times to take pills (one respondent), and problems taking pills with instructions 
(one respondent). 
 
Table 4.2 Reasons of respondents for missing to take antiretroviral drugs 
 
No Reason for missing antiretroviral drugs Proportion % 
1 Simply forgot 16/338 21,9 
2 Too busy 16/338 21,9 
3 Away from home 13/338 17,8 
4 Ran out of pills 8/338 10,9 
5 Secrecy to swallow pills 5/338 6,8 
6 A change in daily routine 5/338 6,8 
7 Fear side-effects 2/338 2,8 
8 Too many pills 2/338 2,8 
9 Felt sick 2/338 2,8 
10 Felt depressed/overwhelmed 1/338 1,4 
11 Unable to comply with dietary instructions 1/338 1,4 
12 Felt asleep 1/338 1,4 
13 Too many times to swallow pills 1/338 1,4 
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Figure 4.17 Major reasons for missing pills 
 
4.8 PATIENT REPORTED RATE OF ADHERENCE 
 
Adherence assessments to ART are summarised in table 4.3. About 93,8% of the 
participants claimed never to have missed a single dose of medication in the week 
before the assessment and hence found to be adherent by self-report, based on the 
definition outlined in the methods above. The one day and three days adherence rate 
was 99,7% and 96,5% respectively.  
 
Table 4.3 Self-reported adherence among respondents 
 
 Adherence 
(>95 % doses correctly taken) 
Yes No 
Previous 1 day 339 (99,7%) 1 (0,3%) 
Previous 3 days 328 (96,5%) 12 (3,5%) 
Previous 7 days 319 (93,8%) 21 (6,2%) 
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Figure 4.18 Self-reported adherence score 
 
4.9 OVERVIEW OF RESEARCH FINDINGS 
 
Presented below are variables associated with adherence: Univariate and multivariate 
binary logistic regression analysis. All variables were dichotomised to fit the model and 
they were screened to identify candidate variables by using univariate analysis at a P-
value of 0,25. A higher P-value (0,25) was used not to miss potential variables for entry 
into the multivariate model. Table 4.2 shows the crude ORs for variables identified as 
correlates of adherence, which were statistically significant in the univariate binary 
logistic regression analysis.  
 
Non-adherence was common among those: aged between 18 and 30 years, with no 
education; who were not married; who had no pipe water supply; those without 
electricity in their homes; who perceived a lack of assistance from providers; who 
perceived the HCPs did not keep information confidentially; who had language barriers 
with providers; as well as those who were treated with a psychiatric illness.   
 
All the other variables included under socio-demography, disease, patient-provider 
relationship and clinical setting, family support and illness, and HIV and ART knowledge 
related factors were not found to be significantly associated with adherence at P<0.25. 
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Candidate variables significantly associated with ART adherence in the univariate 
analysis at P<0.25 were also re-evaluated again with adherence as a dependent 
variable using the multivariate logistic model.  
 
All the variables found to be associated with adherence on the univariate analysis 
remained significantly associated with adherence on the multivariate analysis (table 4.4) 
 
Table 4.4 Factors predicting adherence among respondents 
 
Characteristics Did you miss ≥ one 
dose over the last seven 
days 
COR (95%) AOR (95%) 
No Yes 
2. Age in years 
□ 18-30 
□ over 31 
107 
210 
12 
9 
2.61(1.06-6.40)* 
1 
3.45 (1.11-10.66)* 
1 
3. Your level of education 
□ no education 
□ educated 
74 
242 
13 
8 
5.31(2.12-13.31)*** 
1 
5.06 (1.64-15.60)** 
1 
4. Marital status 
□  none married 
□  married( incl. de facto) 
174 
142 
17 
4 
3.46 (1.14-10.53)*** 
1 
2.37 (1.65-8.60)* 
1 
9. Is your water supply 
source from a pipe? 
□ yes 
□ no 
273 
42 
13 
7 
0.28 (0.10-0.75)** 
1 
0.37 (0.05-0.92)* 
1 
10. Is there electricity in 
your house? 
□ yes 
□ no 
290 
26 
16 
5 
0.28 (0.09-0.84)* 
1 
0.33 (0.08-0.98)* 
1 
16. The HCP is accessible 
when I need her/him 
□ yes 
□ no 
311 
6 
16 
5 
0.06 (0.01-0.22)*** 
1 
0.11(0.01-0.99)* 
1 
17. The HCP keeps 
information discussed 
confidentially 
□ yes 
□ no 
311 
6 
17 
4 
0.08(0.02-0.31)*** 
1 
0.33( 0.03-0.58)** 
1 
18. Do you have language 
barrier with providers? 
□ yes 
□ no 
12 
307 
4 
17 
6.02 (1.75-20.64)** 
1 
2.76 (1.61-12.44)* 
1 
 24. Have you ever been 
treated for a psychiatric 
illness? 
□ yes 
□ no 
44 
267 
8 
13 
3.73 (1.46-9.52)** 
1 
3.56 (1.16-10.93)* 
1 
 
*** Significant at p<0.001, ** significant at p<0.01, * significant at p<0.05 
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4.10 CONCLUSION 
 
The main contents included in this chapter are: socio-demographic data, health care 
facility and providers influence on adherence to ART, disease factors, psychosocial 
factors (family support and illness factors), HIV and ART knowledge, reasons for 
missing antiretroviral drugs, patient reported rate of adherence, overview of research 
findings, and finally, a conclusion with respect to the chapter. 
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CHAPTER 5 
 
DISCUSSIONS OF THE STUDY 
 
5.1 INTRODUCTION 
 
This chapter presents a discussion based on the major findings presented in chapter 4. 
Findings that are discussed include demographic characteristics, healthcare facility and 
providers influence on adherence to ART, psychosocial factors (family support and 
illness factors), reasons for missing antiretroviral drugs, and patient reported rate of 
adherence.  
 
From the study data there were a number of individual (socio-demographic), 
psychosocial, healthcare facility and providers (health care system) variables, which 
were significantly associated with adherence. These are young age, low level of 
education, being single, poor housing infrastructure (lack of electricity and pipe water), 
perception of difficult access to providers and lack of trust in information confidentiality 
in the facility, language barrier with providers, and past treatment history of psychiatric 
illness. 
 
5.2 DISCUSSION ON SOCIO-DEMOGRAPHIC DATA 
 
 
There were more females than males who participated in the study. Sixty-two percent 
(n=208) of the total respondents were females and this confirms the fact that more 
females than males are enrolled in care in this hospital. This may also confirm the fact 
that women have a higher HIV prevalence (1,9%) than men (1%) in Ethiopia (CSA 
2012:231). 
 
The respondents who participated in this study were aged from 18 to 51 years old and 
above. The majority of them were aged between 20 and 50. According to EDHS 2011, 
for women, HIV prevalence increases with age to a peak of 3.7% at the ages of age 30 
to 34.  
 
For men, HIV prevalence increases from 0% at the age of 15 to 19 to 3% at ages of 35 
to 39 and drops thereafter (CSA 2012:234). In this study, 52% of the participants were 
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aged between 31 and 40, which have confirmed the national findings: Nationally, for 
both genders HIV prevalence is higher at ages 30 to 40 (CSA 2012:234).  
 
This indicates that age is an important demographic factor that should be given due 
attention in designing important interventions for people living with HIV. 
 
The study showed that the majority of the participants were married (43,3%) followed by 
single (23,4%); this is, however, against the national pattern. The EDHS documented 
that widowed and divorced respondents (12,2% and 5,2%, respectively) are much more 
likely to be HIV positive than those who are married and those who have never been 
married (CSA 2012:236). This finding raises a need for more effort to be geared 
towards partner testing and disclosure to avoid marital HIV infection in discordant 
couples and to fight stigma at home. 
 
Younger ages, low level of education, being single and lack of pipe water and electricity, 
were found to be statistically significantly associated with non-adherence in this study. It 
has been shown that demographic factors are not consistently associated with 
adherence to ART (Fong et al 2003:133-138).  
 
However, demographic factors are closely linked to socioeconomic status or livelihood, 
which encompasses access to resources such as food, electricity, pipe water, 
educational opportunities, housing, and health facilities (Rachlis et al 2011:1). The 
literature on livelihood and ART adherence is at its early stage (Rachlis et al 2011:6).  
 
Education level and income were the two most frequently studied livelihood factors and 
the latter demonstrated a significant association with adherence. Education level is a 
determinant factor for self-efficacy, which is defined as the conviction that one can 
successfully execute a specific behaviour (Barclay, Hinkin, Castellon, Mason, Reinhard, 
Marion, Levine & Durvasula 2007:3). Self efficacy is in turn a positive determinant for 
adherence although some argue that educated patients might be busy and get no time 
to take their pills (Rachlis et al 2011:6).  
 
A 2011 meta-analysis focused on ART programmes in resource-poor settings reported 
that when medications were provided free-of-charge, there was a higher probability of 
achieving adherence and undetectable viral loads compared to situations where 
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patients were required to pay for treatment (Ivers, Kendrick & Doucette 2005:217-224). 
Even in the availability of free drugs, however, the cost of transportation to go to the 
clinic can still be a barrier to adherence.  
 
Patients who are sources of income choose either to feed their family or to spend the 
small money for transportation (Rachlis et al 2011:8). Food insecurity as a result of low 
income was also mentioned to be associated with decreased adherence to antiretroviral 
drugs in Africa. This may be as a result of patients’ thinking that antiretroviral drugs 
need to be taken with food to avoid gastrointestinal upset, which may lead to poor 
adherence (Rachlis et al 2011:8). 
 
Social factors such as marital status and having children can affect adherence possibly 
in two opposite ways: While the desire to care for families may be a strong motivator for 
patients to adhere, patients may fear to disclose to their sexual partner to avoid 
stigmatisation, discrimination, and potentially abandonment. The lack of family support 
because of failure to reveal HIV status can lead to poor adherence (Atkinson, 
Schönnesson, Williams & Timpson 2008:2; Rachlis et al 2011:8). 
 
Tusiime et al (2008:208-209) said studies report conflicting evidence about the 
association between socio-demographic factors and adherence behaviour; when an 
association is found, the direction is towards lower levels of adherence with younger 
age, being single, non-white race/ethnicity, and lower income, which may be due to 
uncontrolled confounding by other factors. 
 
The results from this study demonstrate that age, marital status, level of education and 
poor housing conditions have an effect on ART adherence. This could be due to 
significantly interacting with other variables, which possibly include whether a patient 
resides in an urban or a rural setting, has food insecurity, own a cell phone, what their 
reasons are for taking the first HIV test, and so forth, which this study failed to show but 
other studies did (Maqutu, Zewotir, North, Naidoo & Grobler 2010:6). 
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5.3 DISCUSSION ON HEALTHCARE FACILITY AND PROVIDERS INFLUENCE 
ON ADHERENCE TO ART 
 
This study demonstrates that perception of difficult access to providers, lack of trust in 
information confidentiality in the facility, and language barrier with providers, are 
associated with non-adherence to ART. This is consistent with a previously published 
study that reported that poor self-reported access to medical care is strongly associated 
with HIV stigma (Sayles, Wong, Kinsler, Martins & Cunningham 2009:1107). It could 
itself be as a result of the perceived discrimination and social inequities that are key to 
the development of stigma (Sayles et al 2009:1105) that is, PLWH who experience 
greater stigmatisation might perceive more difficulty accessing care because fear of 
rejection and discrimination (consequences of stigma) may lead them to perceive the 
healthcare setting as intolerant and inaccessible.  
 
Sayles et al (2009:1105) further describe that mental health attenuates the association 
between stigma and suboptimal ART adherence, implying that the relationship between 
stigma and ART adherence is partially mediated by low mental health status. However, 
the interrelationship and pathways between stigma and other factors known to be 
associated with adherence such as social support, self-efficacy and attitudes toward 
medication need to be further delineated in future studies in order to identify targets for 
effective intervention programs. 
 
5.4 DISCUSSION ON PSYCHOSOCIAL FACTORS (FAMILY SUPPORT AND 
ILLNESS FACTORS) 
 
While past history of treatment for psychiatric illness was significantly associated with 
adherence, depression was not specifically found to be significantly associated with 
adherence in this study. However, the literature demonstrates that depression is 
prevalent among persons with HIV infection and has been linked to suboptimal 
adherence to ART (Kacanek, Jacobson, Spiegelman, Wanke, Isaac & Wilson 2010:5; 
Walkup, Wei, Sambamoorthi & Crystal 2008: 1-2). 
 
Kacanek et al (2010:5) state that although several cross sectional studies and a few 
longitudinal studies have found associations between depression and suboptimal 
adherence, the causal pathways relating depression to poor adherence remain unclear. 
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Kacanek et al (2010:5) further report: A meta-analysis of depression and adherence to 
medical care regimens in general (not only HIV antiretroviral drugs) found that patients 
with depression had a three-fold higher odds of poor adherence and suggested possible 
mechanisms linking depression to poor adherence to medical treatments. Included in 
these possible mechanisms were the feeling of hopelessness, which often accompanies 
depression, social isolation, and an absence of social support. 
 
Since it is one of the modifiable predictors of adherence that could be targeted in 
interventions, awareness of depression among health professionals caring for HIV 
positive patients needs to be increased in order to intervene appropriately (Amberbir, 
Woldemichael, Getachew, Girma & Deribe 2008:7-8; Walkup et al 2008:6). 
 
In this study, a significant number of patients did not disclose their HIV status to their 
family. Although family support was not significantly associated with adherence in the 
study, social support in general may enhance adherence, either directly in the form of 
reminders, financial help, and emotional backing, or indirectly by buffering the effect of 
those variables that might interfere with adherence, e.g. substance use, life’s stresses, 
anxiety, and depression (Tiyou et al 2010:39; Lehavot, Huh, Walters, King, Andrasik & 
Simoni 2011:186-187). 
 
5.5 DISCUSSION ON REASONS FOR MISSING ANTIRETROVIRAL DRUGS 
 
The reasons patients cited for missing ART doses in this study were similar to what is 
found by many others (Awel 2008:19-20; Maqutu et al 2010:118; Amberbir et al 2008:5) 
(figure 4.17). The most frequently given reasons were: simply forgetting and being too 
busy followed by being away from home and running out of pills.  
 
This was consistent with the findings of many other studies as just cited. The rest of the 
reasons included: a change in daily routine, trying not to be noticed while taking pills, 
the burden of taking pills, fear of side effects, too many pills to take, feeling sick, feeling 
asleep, being depressed or overwhelmed, too many pill times and problems of taking 
pills with dietary instructions. The major reasons are one way or another, all associated 
with either forgetting to take their pills or forgetting/unable to attend their appointments 
for refill. 
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A 2006 large-scale meta-analysis of both quantitative and qualitative studies from 
developing and developed nations of patient-reported reasons for non-adherence found 
that important barriers to adherence are similar across multiple settings and 
heterogeneous countries and identified that fear of disclosure; forgetfulness; a lack of 
understanding of treatment benefits; complicated regimens; and being away from their 
medications were consistent barriers to adherence across developed and developing 
nations. More important to poor settings were issues of access, including financial 
constraints and an interruption of access to medicines (stock-outs) (Mills, Nachega, 
Bangsberg, Singh, Rachlis, Wu, Wilson, Buchan, Gill & Cooper 2006: 2039, 2056). 
 
As mentioned in this study, patients have a range of reasons for failing to comply strictly 
with their regimens. These reasons should be assessed for each patient and patients be 
targeted with comprehensive individualised interventions employing behavioural 
educational strategies to improve ability to fit therapy in their own individual lifestyle and 
treatment cue training such as placing medication at a strategic location and using 
memory aids such as diaries, calendars and pillboxes are likely to impact forgetfulness 
(Horizons … 2004:45; Federal HAPCO and Federal MOH 2007:77). 
 
5.6 DISCUSSION ON PATIENT REPORTED RATE OF ADHERENCE 
 
In the study, the seven days (before the study), three days and one day adherence rate 
for the respondents was found to be 93,8%, 96,5% and 99,7%, respectively. This shows 
that adherence rate drops as the cumulative number of days on ART increases. 
However, it does not prove that adherence decreases the longer patients are on ART. 
To conclude this safely, patients should be monitored for their adherence over time. 
 
The researcher measured ART adherence by self-report using structured interview 
questions that can be subject to overestimation, as patients tend to overstate their 
adherence to treatment. Other measures of adherence, such as pill counts, pharmacy 
records, electronic devices, or therapeutic drug monitoring were not available for the 
study. Even so, measuring adherence using patients’ self-report can be easily replicated 
in most resource-limited settings including Ethiopia making it a good measure for 
comparison (Amberbir et al 2008: 5-7; Reda & Biadgilign 2012:2). 
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In the study, 93,8% of patients were adherent with >95% prescribed doses. This study 
found a better adherence level than previously reported from Ethiopia (Awel 2007:40; 
Tadios & Davey 2006:41) except a study by Amberbir et al (2008:7). It is comparable 
with or relatively higher than those reported in other African countries excluding Rwanda 
(Musiime, Muhairwe, Rutagengwa, Mutimura, Anastos, Hoover, Qiuhu, Munyazesa, 
Emile, Uwineza & Cowan 2011:1), and much higher than that of North America. 
 
According to Reda and Biadgilign (2012:2) pooled analysis, for North American studies 
adherence was 55% (95% CI 49% to 62%), while for African studies adherence was 
77% (95% CI 68% to 85%). To see country specific data, in a study assessing factors 
associated with medication adherence in HIV-infected adults in Nigeria, overall 
adherence was 74% (Igwegbe, Ugboaja & Nwajiaku 2010:238). 
 
A Rwandan study indicates that self-reported adherence to antiretroviral treatment 12 
months after initiating therapy was 100% (354/354) in a cohort of HIV positive Rwandan 
women (Musiime et al 2011:1) while a study from Kenya reports 82% adherence 
(Wakibi, Ng’ang’a & Mbugua 2011:1). These data leave adherence rate of this study 
within the range of adherence rates of PLWH to ART in African settings. These data 
from other African settings and from this study suggest that patients of low socio-
economic status are able to achieve excellent rates of adherence with access to routine 
medical care, subsidised or free ART and free laboratory monitoring (Amberbir et al 
2008:7). 
 
5.7 CONTRIBUTIONS OF THE STUDY 
 
The finding in this study suggests implications for research and practice. The 
contributions of the study are the following: 
 
• Its findings could sensitise programme managers and policy makers to evaluate 
currently practiced strategies and to update them or even change them with new 
ones. 
• The study has a room for further research as it has new questions arising from 
the discussion of the findings.  
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5.8 CONCLUSION 
 
The chapter presented discussion of study findings by using different literatures. The 
subheadings used under this chapter were introduction, discussion on socio-
demographic data, discussion on healthcare facility and providers influence on 
adherence to ART, discussion on psychosocial factors (family support and illness 
factors), discussion on reasons for missing antiretroviral drugs, discussion on patient 
reported rate of adherence and finally the conclusion. 
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CHAPTER 6 
 
CONCLUSIONS, LIMITATIONS AND RECOMMENDATIONS 
 
 
6.1 INTRODUCTION 
 
The aim of the study was to investigate factors that influence adherence to ART among 
adults at Nekemte Hospital in Ethiopia. This chapter presented conclusions based on 
results of a study to answer objectives formulated in Chapter 1 as follows: 
 
• to quantify adherence rate among the study participants in the ART unit 
• to identify factors that influence adherence 
 
The chapter also presented some possible limitations of the study. The findings sited in 
Chapter 4 served as a basis for recommendations in this chapter to bring about better 
adherence and access to ART service in the future, especially for high-risk persons for 
non-adherence to ART, by tackling the factors affecting adherence to ART.  
 
6.2 CONCLUSIONS MADE FROM THIS STUDY 
 
• From the above discussion, the study concludes that adherence is multi-factorial 
and varies significantly by individual and care setting. Psychosocial factors were 
found to impact adherence and should be analysed in more detail by further 
studies. Three psychosocial factors were independently associated with poor 
adherence: the study found that patients perceiving poor access, and those 
perceiving problem in information confidentiality (and possibly experiencing 
stigmatisation), and having psychiatric morbidity (and possibly with less social 
support) are more likely to be non-adherent. Furthermore, individuals without 
electricity and those without pipe water supply, implying low income, are at risk 
for non-adherence. 
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• Using the identified reasons for non-adherence i.e., working on status disclosure 
to family/friend/community and hence having a treatment partner in the 
community, linking patients with financial constraints to community support 
networks, making ART accessible both geographically as well as personal 
access to providers, and providing facility reminders such as pill boxes are likely 
to further improve adherence. Lastly, early diagnosis and management of mental 
illnesses like depression needs special focus. 
 
• The main reason identified in this study as reason for missing to take 
antiretroviral drugs was forgetfulness. A number of strategies have been 
proposed to improve memory to take antiretroviral drugs as prescribed, including 
electronic reminders, easier-to-follow regimens, medication under supervised 
settings, self-monitoring, counselling sessions and other strategies. However, 
some strategies to improve ART adherence require considerable resources, and 
adherence is typically not sustained after the intervention is withdrawn. An 
adherence strategy is needed to be both cost effective and has to account for 
patient outcome, development, and transmission of resistant strains of HIV at 
public health perspective.  
 
• It is of concern that participants with perceived difficult access and confidentiality 
to care were less likely to be adherent, suggesting the need for sustained effort 
to emphasise better access to care and patient information confidentiality, which 
also helps to fight stigma. 
 
• The adherence rate in this group of patients may be considered as success, 
adherence was 95% or greater for 93,8% of the patients. That means adherence 
was quite low in a small subset of patients, but the researcher believes there is a 
tremendous need to strengthen the existing qualities and keeping in mind the 
correlates identified in our study. Adherence has to be improved and monitored 
using multifaceted and repetitive interventions. Since adherence is a dynamic 
process and patient’s behaviour can change over time, there is also a need to 
have a follow-up design, which could yield a more valid average measure of 
adherence as well as its determinants than a cross-sectional self-reported 
adherence assessment. 
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• Unless adherence is closely monitored, the dangers of non-adherence, 
especially drug resistance, may eliminate the only hope available to prolong 
survival of PLWH. 
 
• Determinants like regimen, treatment knowledge, and disease status, found to be 
consistently associated with adherence in many studies were not found to be 
significantly associated with adherence in this study. The lack of significant 
association of regimen and treatment knowledge with adherence in the study 
needs to be rechecked with coverage of more institutions at different settings. 
 
6.3 RECOMMENDATIONS 
 
Based on the results of this study it would be important to recommend that health care 
providers need to:  
 
• Detect and manage depression among patients on ART with a multidisciplinary 
approach. 
• Provide patients with information about their treatment plans. 
• Keep the ART regimens as simple as possible. 
• Involve patients in the treatment plan so that it fits into their daily routine. 
• Ensure that communication with patients is clear during appointments in their 
ART units; this includes a need to assess and be aware of language barriers. 
 
The health care system needs to: 
 
• Improve patients’ confidence, trust, and satisfaction with their relationship with 
healthcare providers, specifically, as these participants indicated, the system 
needs to assess patient information confidentiality gap and to thrive to bring 
perceived confidentiality for the patients. 
• Eliminate the problem of access to the assistance and service patients need. 
• Have a holistic approach to patients to the extent of assessing and dealing with 
their socio economic problems. For instance, the facility can look for PLWH 
organisations and try to find sites for community referral linkage where poor 
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patients can receive free services and financial support as well as being 
beneficiaries in income generating activities after they get seed money from 
these PLWH organisations. Emphasis should also be given to social supports 
that help to remind the patients to take their antiretroviral drugs.  
 
The regional heath bureau or the regional government needs to: 
 
• Do broader observational prospective cohorts study of adherence with larger 
sample from both public and private hospitals so that more practical country 
specific adherence modifying strategies can be designed. 
• Bring care closer to the patients by ART site expansion and increasing access to 
affordable transportation. 
• Implement community-based livelihood development strategies targeted for 
PLWH. 
 
6.4 LIMITATIONS OF THE STUDY 
 
The researcher feels that this study has the following possible limitations that warrant 
mention: 
 
First, as the study used cross-sectional design, it did not allow the researcher to 
establish a causal relationship between significantly associated variables and treatment 
adherence, as both variables were measured at the same time. 
 
Secondly, “gold standard” for assessment of adherence does not exist, in this study 
adherence was measured using self-report; studies suggest self-report tends to 
overestimate adherence. Social desirability (projection of a positive image) could have 
induced an overestimation of adherence, but the researcher tried to minimise that by 
explaining to each patient that it was not always easy to adhere to medical treatments in 
general (Joubert & Ehrlich 2007:163).  
 
The patients were also informed that their answers would not interfere with the care 
they received. Furthermore, structured self-report has been reliably associated with both 
objective measures of adherence and viral load.  
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The same limitation i.e. lacks of “gold standard” to assess depression, satisfaction, 
access, confidentiality, and so forth, made the researcher to shift to participants’ 
perceived assessment. 
 
It would have been better to utilise a combination of methodologies (both quantitative 
and qualitative), which could have helped the study to cover wider concepts related to 
ART adherence and complement the findings in each method by the other. 
 
Another limitation of the study is that the researcher was unable to corroborate patient 
self-report of adherence with CD4 cell responses because of financial and logistic 
barriers.  
 
The other limitation that the study possibly has is that it did not segregate patients into 
cohorts of treatment (at least yearly cohort batches) according to the date of initiation of 
ART to see issues specific to every cohort. For example, forgetfulness to take pills, 
which was given by the majority of the respondents as a reason for missing pills, might 
be a problem of beginners of treatment until a certain period of time, which can improve 
later as patients stay more on treatment. 
 
This could have been unreasonably concluded as a main reason if the majority of the 
participants were by chance those who started ART later than the rest. On the other 
hand, if again only a smaller number of the participants were by chance from those who 
were chronically on ART, they could develop “treatment fatigue”, which is not usually 
mentioned and appropriately addressed as a barrier both in the literature as well as by 
the HIV clinicians. As a result, patients were not tightly adherent to their medication but 
this variable, which can be more significant in them, could have been masked by other 
variables predominantly cited by those newer patients (Federal HAPCO and Federal 
Ministry of Health 2007:75).  
 
However, the researcher believes that this was handled by applying random sampling 
procedure, which provides reassurance that the sample is representative of the 
population of interest so that inclusion of every year of cohort of patients in the study 
can be safely assumed. 
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Finally, since the study was performed only in one public hospital in Oromiya and since 
it was not a longitudinal or a follow-up study, the generalisability of our findings may be 
limited. Whether the study findings would differ in other subpopulations of PLWH 
remains to be determined. As adherence and combination therapy are dynamic and 
continuous process there is a need for more research. The study needs to be replicated 
with a more diverse sample and different settings to see if the issues related to 
adherence are similar across the HIV patient population. 
 
6.5 CONCLUDING REMARKS 
 
This study has shown that good adherence is achievable in resource-limited settings, 
however, more has to be done to achieve adherence rate of 99% or even 100% 
reported elsewhere.  
 
It is important to state that self-report used to measure adherence is not gold standard 
for adherence measurement, but it has been reported to be sufficient enough to assess 
adherence when pill count is not possible and electronic monitoring devices and indirect 
methods like serum antiretroviral drug level measurement are not feasible. 
 
This approach of assessing multiple interrelated barriers within a population may prove 
to be very useful for the development of future adherence interventions, as an individual 
who faces multiple barriers can be offered more than a single intervention to intervene 
with non-adherence. 
 
Future adherence research and interventions should not focus solely on medication 
adherence, but also the clinical outcome and quality of life of patients on ART. To know 
appointment adherence and patient retention is equally important because those lost-to-
follow-up patients might have carried drug resistant HIV strains. Tracing this group of 
patients, returning them to care, and preventing treatment discontinuation by enhancing 
adherence counselling for a higher-risk population by developing simple and 
inexpensive strategies that focus on improving adherence follow-up needs as equal 
attention as those patients in care with regards to the task of achieving adherence to 
treatment. 
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It is also important to note the ideal study of adherence would be one that occurs across 
several phases and incorporates both qualitative and quantitative elements because 
many barriers to adherence can be addressed with patients through discussion and 
education regarding treatment benefits to health. 
 
 
59 
LIST OF REFERENCES 
 
Amberbir, A, Woldemichael, K, Getachew, S, Girma, B & Deribe, K. 2008. Predictors of 
adherence to antiretroviral therapy among HIV-infected persons: a prospective study in 
Southwest Ethiopia. BMC Public Health 8:265. doi:10.1186/1471-2458-8-265:5-8.  
From: http://www.biomedcentral.com/1471-2458/8/265 (accessed 4 May 2012). 
From: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 2518153 (accessed 4 May 2012). 
 
Atkinson, JS, Schönnesson, LN, Williams, ML &Timpson, SC. 2008. Associations 
among correlates of schedule adherence to antiretroviral therapy (ART): A path analysis 
of a sample of crack cocaine using sexually active African–Americans with HIV 
infection. AIDS Care. 2008 February; 20(2):253-262. doi: 10.1080/09540120701506788: 
2,  
From: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 2860722 (accessed 3 May 2012). 
 
Awel, M. 2008. Antiretroviral treatment adherence and its determinants among people 
living with HIV/AIDS on highly active antiretroviral therapy at two hospitals in Oromya 
regional state, in Renewing commitment to sanitation in the new millennium: aligning 
with international year of sanitation (IYS). Addis Ababa: Ethiopian Public Health 
Association:19-20. 
 
Barclay, TR, Hinkin, CH, Castellon, SA, Mason, KI, Reinhard, MJ, Marion, SD, Levine, 
AJ & Durvasula, RS. 2007. Age-associated predictors of medication adherence in HIV 
positive adults: health beliefs, self-efficacy, and neuro cognitive status. Health Psychol 
26(1):3.  
From: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC 2863998 (accessed 17 May 
2012). 
 
Burns, N & Grove, SK. 2005. The practice of nursing research: conduct, critique, and 
utilization. 5th edition. St Louis: Elsevier/Saunders: 2, 24 and 365. 
 
Central Statistic Agency. 2012. Ethiopia demographic and health survey 2011. Addis 
Ababa 3:231-244. 
 
El-Sadr, WM, Affrunti, M, Gamble, T & Zerbe, A. 2010. Antiretroviral therapy: a 
promising HIV prevention strategy? NC 10032, USA: ICAP:5-6. 
From: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074403/ (accessed on 5 February 
2011). 
 
Federal HAPCO. 2012. National HIV/AIDS estimates in Ethiopia. Addis Ababa: 
Ethiopia:1. 
 
Federal HAPCO and Federal MOH. 2007. Guidelines for management of opportunistic 
infections and anti-retroviral treatment in adolescents and adults in Ethiopia. Addis 
Ababa: Ethiopia:50-62, 75 and 77. 
 
Federal MOH and Federal HAPCO. 2007. Guideline for HIV counselling and testing in 
Ethiopia. Addis Ababa: Ethiopia:4. 
 
 
60 
Fong, OW, Ho, CF, Fung, LY, Lee, FK, Tse, WH, Yuen, CY, Sin, KP & Wong, KH. 2003. 
Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese 
HIV/AIDS patients. HIV Medicine 4(2):133-138.  
 
Gardner, EM, Burman, WJ, Steiner, JF, Anderson, PL & Bangsberg, DR. 2009. 
Antiretroviral medication adherence and the development of class-specific antiretroviral 
resistance. NIH Public Access, USA:9. 
From http://www.ncbi.Nlm.nih.gov/pmc/articles/PMC 2704206/pdf/nihms-111114.pdf 
(accessed 4 May 2012). 
 
Gusdal, AK, Obua, C, Andualem, T, Wahstrom, R, Tomson, G, Peterson, S, Ekstrom, 
AM, Thorson, A, Charlker, J & Forschen, G. 2009. Voices of adherence to ART in 
Ethiopia and Uganda: a matter of choice or simply not an option? AIDS Care 
21(111):1381-1387. 
 
Haubrich, RH, Little, SJ, Currier, JS, Forthal, DN, Kemper, CA, Beall, G, Johnson, ND, 
Dube, MP, Hwang, JY & McCutchan, JA. 1999. The value of patient-reported 
adherence to antiretroviral therapy in predicting virologic and immunologic response: 
California Collaborative Treatment Group. AIDS 13(9):1099-1107 (accessed 22 April 
2012). 
 
HIV/AIDS Prevention and Control Office. 2008-2009. Multi-sectoral HIV/AIDS response 
annual monitoring and evaluation report. 4th edition. Addis Ababa: Planning, Monitoring 
and Evaluation Directorate:37. 
 
Horizons/Population Council, International Center for Reproductive Health and Coast 
Province General Hospital, Mombasa-Kenya. 2004. Adherence to antiretroviral therapy 
in adults: a guide for trainers. Nairobi: Population Council. 
 
Igwegbe, AO, Ugboaja, JO & Nwajiaku, LA. 2010. Prevalence and determinants of non-
adherence to antiretroviral therapy among HIV-positive pregnant women in Nnewi, 
Nigeria. International Journal of Medicine and Medical Sciences 2(8):238-245.  
From http://www.academicjournals.org/ijmms (accessed 7 June 2012). 
 
Ingersoll, KS & Cohen, J. 2008. The impact of medication regimen factors on adherence 
to chronic treatment: a review of literature. J Behav Med 31(3):213-224. 
doi:10.1007/s10865-007-9147-y:2. 
From: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 2868342 (accessed 14 June 
2012). 
 
Ivers, LC, Kendrick, D & Doucette, K. 2005. Efficacy of antiretroviral therapy programs 
in resource-poor settings: a meta-analysis of the published literature. Clinical Infectious 
Diseases 41(2):217-224. 
From: http://cidoxfordjournals.org/content41/2/217.full (accessed 28 June 2012). 
 
Joubert, G & Ehrlich, R (eds). 2007. Epidemiology: a research manual for South Africa. 
2ndedition. Cape Town: Oxford University Press:7, 163. 
  
 
61 
 
Kacanek, D, Jacobson, DL, Spiegelman, D, Wanke, C, Isaac, R & Wilson, IB. 2010. 
Incident depression symptoms are associated with poorer HAART adherence: a 
longitudinal analysis from the Nutrition for Healthy Living (NFHL) study. J Acquir 
Immune Defic Syndr 53(2):266 – 272. doi:10.1097/QAI.0b013e3181b720e7:5. 
From: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 2877126 (accessed 1 May 2012). 
 
Lange, JMA, Katabira E & Sow PS. 2008. Antiretroviral therapy in resource-poor 
settings: challenges, research priorities, opportunities, in Global HIV/AIDS medicine, 
edited by PA Volberding, MA Sande, WC Greene & LMA Lange. 1st edition. 
Philadelphia: Elsevier/Saunders:615.  
 
Laufs, U, Rettig-Ewen, V & Böhm, M. 2010. Strategies to improve drug adherence. 
European Heart Journal 32:260-268.  
From: http://www.eurheartj.oxfordjournals.org/content/32/3/264.full.pdf (accessed 3 May 
2012). 
 
Le, CT. 2003. Introductory biostatistics. Hoboken, New Jersey: John Wiley & Sons:452. 
 
Lehavot, K, Huh, D, Walters, KL, King, KM, Andrasik, MP & Simoni, JM. 2011. Buffering 
effects of general and medication-specific social support on the association between 
substance use and HIV medication adherence. AIDS Patient Care and STDS 25(3):186-
187.  
From: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 3048831 (accessed 4 May 2012). 
 
Maqutu, D, Zewotir, T, North, D, Naidoo, K & Grobler, A. 2010. Factors affecting first-
month adherence to antiretroviral therapy among HIV-positive adults in South Africa. Afr 
J AIDS Res 9(2):117-124. doi:10.2989/16085906.2010.517478:6.  
From: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC 31379329 (accessed 4 May 
2012). 
 
Markos, E, Alemayehu, W & Davey, G. 2008. Adherence to ART in PLWHA at Yirgalem 
Hospital, South Ethiopia. Ethiopian Journal of Health Development 22(2):174-179. 
 
Merry, C & Flexner, CW. 2008. Pharmacology of antiretroviral drugs, in Global 
HIV/AIDS Medicine, edited by PA Volberding, MA Sande, WC Greene & JMA Lange. 1st 
edition. Philadelphia: Elsevier/Saunders:171-179.  
 
Mills, EJ, Nachega, JB, Bangsberg, DR, Singh, S, Rachlis, B, Wu, P, Wilson, K, 
Buchan, I, Gill. CJ & Cooper, C. 2006. Adherence to HAART: a systematic review of 
developed and developing nation patient reported barriers and facilitators. PLoS Med 
3(11):e438:2039, 2056.   
From: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC 1637123 (accessed 4 May 2012). 
 
Mills, EJ, Nachega, JB, Buchan I, Orbinski, J, Attaran A, Singh, S, Rachlis, B, Wu, P, 
Cooper, C, Thabane, L, Wilson, K, Guyatt, GH & Bangsberg, DR. 2009. Adherence to 
antiretroviral therapy in Sub-Saharan Africa and North America: a meta-analysis. JAMA 
296(6):679-690.  
From: http://jama.ama-assn.org/cgi/content/full/296/6/679 (accessed 22 April 2012). 
  
 
62 
 
Musiime, S, Muhairwe, F, Rutagengwa, A, Mutimura, E, Anastos, K, Hoover, DR, 
Qiuhu, S, Munyazesa,E, Emile,I, Uwineza, A & Cowan, E. 2011. Adherence to highly 
active antiretroviral treatment in HIV-infected Rwandan women. PLoS ONE 
6(11):e27832.doi:10.1371/journal.pone.0027832:1.  
From: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 3219684 (accessed 7 June 2012). 
 
Oromia map. 2005.  
From: http://www.ocha-eth.org/Maps/downloadables/OROMIA.pdf (accessed 17 
November 2009). 
 
Panel on Antiretroviral Guidelines for Adults and Adolescents. 2012. Guidelines for the 
use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of 
Health and Human Services:K1. 
From: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 
27 April 2012). 
 
Paterson, DL, Swindells, S, Mohr, J, Brester, M, Vergis, EN, Squier, C, Wagener, MM & 
Singh, N. 2000. Adherence to protease inhibitor therapy and outcomes in patients with 
HIV infection. Annals of Internal Medicine 133:21-30.  
From: http://www.ncbi.nim.gov/pubmed/10877736 (accessed on 22 April 2012). 
 
Rachlis, BS, Mills, EJ & Cole, DC. 2011. Livelihood security and adherence to 
antiretroviral therapy in low and middle income settings: a systematic review. PLoS 
ONE 6(5):6, 8. 
From: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC 2386831 (accessed 30 April 
2012). 
 
Reda, AA & Biadgilign, S. 2012. Determinants of adherence to antiretroviral therapy 
among HIV-infected patients in Africa: AIDS Research and Treatment Volume 2012, 
Article ID 574656, doi:10.1155/2012/574656. Hindawi Publishing Corporation:2-3. 
 
Rosen, S, Fox, MP,& Gill, CJ. 2007. Patient retention in antiretroviral therapy programs 
in Sub-Saharan Africa: a systematic review: PLoS Med 4(10):e298. doi:10. 
1371/journal.pmed.0040298:1695-1696. 
From: plosmedicine.org/article/info:doi/10.1371/1371/journal.pmed.0040298 (accessed 
27 April 2012). 
 
Rouleau, D, Fortin, C, Trottie, B, Lalonde, R, Lapointe, N, Cote, P, Routy, JP, Matte, 
MF, Tsarevsky, I & Baril, JG. 2011. Antiretroviral therapy for adults infected with HIV: 
Guidelines for health care professionals from the Quebec HIV care committee. Can J 
Infect Dis Med Microbiol 22(2):52-60.  
From: http://www.skhiv.ca/Journal%20Article.pdf (accessed 17 April 2012). 
 
Sayles, JN, Wong, MD, Kinsler, JJ, Martins, D & Cunningham, WE. 2009. The 
association of stigma with self-reported access to medical care and antiretroviral 
therapy adherence in persons living with HIV/AIDS. J Gen Intern Med 24(10):1101-
1108.  
From: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC (accessed 3 May 2012). 
  
 
63 
 
Steel, G, Nwokike, J & Joshi, M. 2007. Development of a multi-method tool to measure 
art adherence in resource-constrained settings: the South Africa experience. Submitted 
to the US. Agency for International Development by the Rational Pharmaceutical 
Management Plus Program. Arlington, VA: Management Sciences for Health:2-4, 6-8.  
From: http://www.msh.org/projects/rpmplus/document/upload/07-157-ART-Adherence-
Measurement-Tool_Technical (accessed 15 May 2012). 
 
Stommel, M & Wills, CE. 2004. Clinical research: concepts and principles for advanced 
practice nurses. Philadelphia: Lippincott, Williams & Wilkins:3. 
 
Tadios, Y & Davey, G. 2006. Antiretroviral treatment adherence and its correlates in 
Addis Ababa, Ethiopia. Ethiopian Medical Journal 44(3):41, 237-245. 
 
Tiyou, A, Belachew, T, Alemseged, F & Biadgilign, S. 2010. Predictors of adherence to 
antiretroviral therapy among people living with HIV/AIDS in resource- limited setting of 
southwest Ethiopia. AIDS Research and Therapy 7:39:1. 
From: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 2988692 (accessed 4 May 2012). 
From: http://www.aidsrestherapy.com/content/7/1/39 (accessed 4 May 2012). 
 
Tusiime, JB, Orelland, C & Bangsberg, D. 2008. Adherence to HIV antiretroviral therapy 
in resource-limited settings, in Global HIV/AIDS medicine, edited by PA Volberding, MA 
Sande, WC Greene and JMA Lange. 1st edition. Philadelphia: Elsevier/Saunders:207-
211.  
 
UNAIDS. 2010. Global report: UNAIDS report on the global AIDS epidemic. 
Geneva:WHO: 21, 25, 96, 98, 99 and 106. 
Wakibi, SN, Ng’ang’a, ZW & Mbugua, GG. 2011. Factors associated with non-
adherence to highly active antiretroviral therapy in Nairobi, Kenya. AIDS Research and 
Therapy 8:43:1.    
From: http://www.aidsrestherapy.com/content/8/1/43 (accessed 23 June 2012). 
 
Walkup, J, Wei, W, Sambamoorthi, U & Crystal, S. 2008. Antidepressant treatment and 
adherence to combination antiretroviral therapy among patients with AIDS and 
diagnosed depression. Psychiatr Q 79(1):43-53. doi:10.1007/s11126-007-9055-x:1-2, 6.  
From: http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC 2882936 (accessed 4 May 2012). 
 
WHO. 2003. Adherence to long-term therapies: evidence for action. Geneva: WHO: 3-
11.   
From http://www.who.int/publications/adherence to long-term therapies (accessed 9 
April 2012). 
 
WHO, UNAIDS, UNICEF. 2011. Global HIV/AIDS response. Epidemic update and 
health sector progress towards universal access. Progress report 2011. Geneva: WHO: 
2.  
From: http://www.unicef.org/aids/files/aids_UA2011.pdf (accessed on 13 May 2012). 
 
 Annexure A:  Approval from UNISA 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure B:  Letter seeking consent from Nekemte Referral Hospital 
  
Annexure C:  Letter of approval from Nekemte Referral Hospital 
 
1 
 
Annexure D: Questionnaire 
 
The purpose of this questionnaire is to collect information on factors that affect your ability to take 
your antiretroviral medicines as prescribed; to assess how best to measure your adherence, and to 
develop strategies to assist you better with taking your medications exactly as prescribed.  
 
Date __________________                                                              Interviewer Self             Both 
 
Code no____________________How Administered?           1        2 3 
 
___________________________________________________________________________ 
 
SECTION A: Socio-Demographic 
 
1. Sex:  
□  Male  □  Female 
 
2. Age in years:  
□ 18-19   □ 20-30   □31-40 □   41-50   □ over 51 
 
3.Your level of education:  
□ No education □ Primary □ Secondary□Tertiary 
 
4.  Marital status: 
□Never married □Married (incl. de facto) 
□Separated□ Divorced □Widow/widower 
 
5. Religion  
□ Muslim □Orthodox□ Protestant□Catholic□Other 
 
6. Do you live with family?  
□ Yes□ No 
 
7. How many people live in the house including you? 
□ Less than 3    □ 3 to 6□ 7 to 9      □ More than 10 
 
8. How many bedrooms are there in the house? 
□ 1  □ 2              □3□ More than 3 
 
9. Is your water supply source from a pipe?                    
□ Yes                     □No 
 
 
10. Is there electricity in your house? 
□ Yes  □No 
 
  
 
2 
11. Are you employed? 
□ Yes  □ No 
 
12. What is your average monthly income? (Include pension, public assistance, support from 
family/friends, etc.) 
□ Less than ETBR 200 □ ETBR 200-499□ ETBR 500- 1000   
□ETBR 1000-1500  □ More than 1500 ETBR  
 
 
SECTION B: PATIENT-PROVIDER RELATIONSHIP AND CLINICAL SETTING 
(Care factors) 
13.The HCP involves me as a partner in care□ Yes      □ No 
14.The HCP helps me to understand their care□ Yes       □ No 
15.The HCP supports decisions                                                                □ Yes       □ No 
16.The HCP is accessible when I need her/him□ Yes       □ No 
17.The HCP keeps information discussed confidentially□ Yes      □ No 
18. Do you have language barrier with providers□Yes □ No 
 
SECTION C: DISEASE CHARACTERISTICS (Disease factors) 
 
19. How long has it been since you were diagnosed with HIV infection? 
 
□ 1 year   □ 1-3 years   □4-6 years   □ more than 6 years 
 
20. Do you have HIV-related treatment currently? 
□ Yes   □ No 
 
21.Have you had hospitalisations over the last one year? 
□ Yes  □No 
 
SECTION D: PSYCHOSOCIAL HISTORY (Family support and illness factors) 
 
 
22. Is your family aware of your HIV status? 
□Yes   □No  □Don’t know 
 
23. If Yes and you are taking antiretroviral medication do they help you take your  
medication? 
□ A lot □ Somewhat   □ A little   □ Never   □ Not applicable  
 
24. Have you ever been treated for a psychiatric illness? 
□ Yes □ No 
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25. In the past four (4) weeks, have you been unable to cope with all the things you need to 
do? 
□ Never □ Sometimes □Often  □Always 
 
26. In the past four (4) weeks, have you felt down (depressed)? 
□ Never   □Sometimes □ Often □ Always 
 
27. If you are feeling down (depressed), is there someone you can talk to? 
□ Yes  □No 
 
28.  Do you use substance to relieve stress or when you have a problem?  
□Yes  □No 
 
 
SECTION E: HIV and HAART Knowledge 
 
29. Do you understand ways of HIV transmission 
□Yes □ No □Don’t know  
If Yes, please explain: 
________________________________________________________________________________
______________________________________________________________________ 
It will be marked by a physician as: 
□ Very good   □ Good   □Fair   □ Poor 
 
30. Do you understand the difference between HIV and AIDS? 
□Yes □ No □Don’t know  
 
If Yes, please explain: 
________________________________________________________________________________
________________________________________________________________________________ 
It will be marked by a physician as: 
□ Very good   □ Good   □Fair   □ Poor 
 
31. Do you know what a CD4+ T cell count measures? 
□Yes          □No□Don’t know 
 
If Yes, please explain______________________________________________________________ 
 
It will be marked by a physician as: 
□Very good□ Good   □Fair   □ Poor 
 
32. Do you know how antiretrovirals work? 
□Yes □ No □Don’t know  
 
If Yes, please 
explain___________________________________________________________________________
________________________________________________________________________________ 
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It will be marked by a physician as: 
□Very good □ Good   □Fair   □ Poor   
 
 The following statements are attempts to capture your knowledge and beliefs about taking 
antiretroviral medicines. 
 
33. I have to take them for the rest of my life. 
□ Strongly Agree   □ Agree  □    Don’t know □ Disagree □  Strongly Disagree 
 
34. Some antiretrovirals have to be taken on an empty stomach and 
others may be taken with food. 
□ Strongly Agree   □ Agree  □    Don’t know □ Disagree □  Strongly Disagree 
 
35. The time at which the medication is taken will influence its effectiveness. 
□ Strongly Agree   □ Agree  □    Don’t know □ Disagree □  Strongly Disagree 
 
36. Missing doses and/or taking them late or incorrectly will 
determine if the treatment works. 
□ Strongly Agree   □ Agree  □    Don’t know □ Disagree □  Strongly Disagree 
 
37. For my medicine to work best, I should not miss a dose, nor take 
it late or incorrectly. 
□ Strongly Agree   □ Agree  □    Don’t know □ Disagree □  Strongly Disagree 
 
38. Drug resistance develops when my antiretrovirals are missed and/or 
taken late or incorrectly. 
□ Strongly Agree   □ Agree  □    Don’t know □ Disagree □  Strongly Disagree 
 
 
SECTION F: Treatment Regimen Adherence Assessment 
(Note: IF YOU TOOK ONLY A PORTION OF A DOSE, OR TOOK WITH DELAY OF ≥2 HRS ON 
ONE OR MORE OF THESE DAYS, PLEASE REPORT THE DOSE(S) AS BEING MISSED.) 
 
39. How many doses should you take per day? 
□One     □Two 
40. Did you miss   ≥one dose in last 24 hrs? 
□Yes      □No 
41. Did you miss ≥one dose in the last 72 hours? 
□Yes□No  
42. Did you miss   ≥one dose over the last seven days? 
□Yes       □No 
 
 
  
 
5 
SECTION G: Reasons for missing ARVs 
 
People may miss taking their medications for various reasons. Here is a list of possible 
reasons whyyou may miss taking your medications. Don’t worry about telling us that you 
don’t take all your pills. We need to know what is really happening, not what you think we 
“want to hear.” 
How often have you missed taking your medications because you: (Circle one response for 
each question.) 
                   Never          Rarely          Sometimes          Often 
43. Were away from home?  
 
 
44. Were busy with other things?         
 
45. Simply forgot?                                             
 
 
46. Had too many pills to take?                        
 
 
47. Too many times to take the pills 
 
 
48. Wanted to avoid side effects?  
 
 
 
Never          Rarely          Sometimes          Often 
49. Did not want others to notice                       
you taking medication? 
 
 
50. Had a change in daily routine?                     
 
51. Fell asleep/slept through                             
 
dose time? 
 
52. Felt sick or ill?                                              
 
 
53. Felt depressed/overwhelmed?                   
 
 
54. Had problems taking pills with instructions  
(With meals, empty stomach, etc.)? 
 
 
55. Ran out of pills?                                           
 
0 1 2 3 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
0 
0
0 
0 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
1 2 3 
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Thank you very much for participating in this study and completing these 
questions! 
__________________________________________________________________________ 
 
 
 
